Skip to Content
Merck
  • In vitro and in vivo investigations of upconversion and NIR emitting Gd₂O₃:Er³⁺,Yb³⁺ nanostructures for biomedical applications.

In vitro and in vivo investigations of upconversion and NIR emitting Gd₂O₃:Er³⁺,Yb³⁺ nanostructures for biomedical applications.

Journal of materials science. Materials in medicine (2012-05-17)
Eva Hemmer, Hiroyuki Takeshita, Tomoyoshi Yamano, Takanori Fujiki, Yvonne Kohl, Karin Löw, Nallusamy Venkatachalam, Hiroshi Hyodo, Hidehiro Kishimoto, Kohei Soga
ABSTRACT

The use of an "over 1000-nm near-infrared (NIR) in vivo fluorescence bioimaging" system based on lanthanide containing inorganic nanostructures emitting in the visible and NIR range under 980-nm excitation is proposed. It may overcome problems of currently used biomarkers including color fading, phototoxicity and scattering. Gd(2)O(3):Er(3+),Yb(3+) nanoparticles and nanorods showing upconversion and NIR emission are synthesized and their cytotoxic behavior is investigated by incubation with B-cell hybridomas and macrophages. Surface modification with PEG-b-PAAc provides the necessary chemical durability reducing the release of toxic Gd(3+) ions. NIR fluorescence microscopy is used to investigate the suitability of the nanostructures as NIR-NIR biomarkers. The in vitro uptake of bare and modified nanostructures by macrophages is investigated by confocal laser scanning microscopy. In vivo investigations revealed nanostructures in liver, lung, kidneys and spleen a few hours after injection into mice, while most of the nanostructures have been removed from the body after 24 h.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Gadolinium(III) oxide, nanopowder, <100 nm particle size (BET), 99.8% trace metals basis
Sigma-Aldrich
Gadolinium(III) oxide, powder, 99.9% trace metals basis
Sigma-Aldrich
Gadolinium(III) oxide, powder, ≥99.99% trace metals basis
Sigma-Aldrich
Gadolinium(III) oxide, ≥99.9%